AZD3293

• CAT Number: I007611
• CAS Number: 1383982-64-6
• Molecular Formula: C26H28N4O
• Molecular Weight: 412.53
• Purity: ≥95%
• Synonyms: lanabecestat; AZD3293; AZD-3293; AZD 3293; LY3314814; LY-3314814; LY 3314814.;(1r,4r)-4-methoxy-5/’/’-methyl-6/’-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3/’H-dispiro[cyclohexane-1,2/’-indene-1/’,2/’/’-imidazol]-4/’/’-amine
• Target: Beta-secretase
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• InChI: InChI=1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1
• InChIKey: WKDNQONLGXOZRG-BOPKNSRXSA-N
• SMILES: CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2

AZD3293(Cat No.: I007611) is a small molecule drug that was developed as a potential treatment for Alzheimer’s disease. It is also known by its generic name “læcanitumab” or its former code name “LY3314814”. AZD3293 is a beta-secretase 1 (BACE1) inhibitor, which means it inhibits the activity of the BACE1 enzyme involved in the production of beta-amyloid peptides. Beta-amyloid peptides are believed to play a role in the formation of amyloid plaques, a hallmark of Alzheimer’s disease. By inhibiting BACE1, AZD3293 aims to reduce the production of beta-amyloid and potentially slow down the progression of the disease.